Table 1.
Baseline characteristics
| Variable | Placebo (N = 26) | TZP 12 mg (N = 29) | TZP 15 mg‐1 (N = 28) | TZP 15 mg‐2 (N = 28) |
|---|---|---|---|---|
| Age (years) | 56.0 ± 10.13 | 61.2 ± 7.56 | 55.5 ± 8.54 | 56.6 ± 9.21 |
| Male, n (%) | 12 (46.2) | 15 (51.7) | 16 (57.1) | 23 (82.1) |
| Diabetes duration (years) | 8.8 ± 6.43 | 10.5 ± 7.90 | 8.2 ± 4.87 | 8.9 ± 6.35 |
| HbA1c (%) | 8.2 ± 1.22 | 8.4 ± 0.90 | 8.5 ± 1.17 | 8.4 ± 1.12 |
| HbA1c (mmol/mol) | 66.4 ± 13.36 | 67.8 ± 9.81 | 69.2 ± 12.80 | 67.8 ± 12.25 |
| FSG (mg/dL) | 168.5 ± 62.06 | 177.9 ± 54.68 | 187.4 ± 72.86 | 194.5 ± 75.96 |
| FSG (mmol/L) | 9.7 ± 3.45 | 9.8 ± 3.04 | 10.4 ± 4.05 | 10.7 ± 4.22 |
| Weight (kg) | 89.6 ± 23.70 | 88.0 ± 17.35 | 88.7 ± 18.21 | 89.6 ± 16.91 |
| BMI (kg/m2) | 32.5 ± 5.70 | 32.0 ± 5.19 | 32.0 ± 5.56 | 31.1 ± 4.21 |
| Waist circumference (cm) | 109.1 ± 15.38 | 107.7 ± 12.23 | 107.0 ± 12.65 | 105.1 ± 12.19 |
|
Metformin use Yes, n (%) |
23 (88.5) | 25 (86.2) | 25 (89.3) | 23 (82.1) |
Abbreviations: BMI, body mass index; FSG, fasting serum glucose; N, total number of patients in that category; n, number of patients; TZP, tirzepatide.All values are presented as mean ± SD unless otherwise noted.